AstraZeneca's Rare Disease Drug Fails to Meet Primary Goal in Late-Stage Trial
📊 AZN — Piyasa Yorumu
▼ down · 60%News indicates that AstraZeneca's rare disease drug has failed a late-stage trial. This could negatively impact the drug's approval process and future revenue potential. While technical indicators present a neutral outlook, with RSI at 52 showing balance and MACD hovering near the signal line, short-term selling pressure may arise, though the decline is expected to be limited.
📊 GOOGL — Piyasa Yorumu
▼ down · 70%GOOGL shares experienced a sharp decline of 8.3% in the last session, falling to 319.77. While the RSI has entered oversold territory at 29.65, MACD values remain negative and below the signal line. The stock is trading well below its 20-day and 50-day moving averages (327.52 and 343.39, respectively). Although the headline is not directly related to GOOGL, AstraZeneca's failed trial result could reduce overall risk appetite in the biotech sector, potentially spilling over into technology stocks. In the short term, technical indicators are likely to remain weak.